Key facts
- This page summarizes Douglas J. Manion's Form 4 filing for Aclaris Therapeutics, Inc. (ACRS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2024, 16:44.
Douglas J. Manion - 01 Jan 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)
- Reporting relationship
- Pres and CEO, Director
- Issuer ticker
- ACRS
- Reported as of
- 01 Jan 2024
- Net transaction value
- -$9,581
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 16:44:56 UTC
- Prior SEC filing
- 03 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas J. Manion filed Form 4 for Aclaris Therapeutics, Inc. (ACRS) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Aug 2023.
- Current net transaction value: -$9,581.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +27,000
- Change %
- +113%
- Price
- Shares after
- 50,938
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
ACRS
transaction
Common Stock
Tax liability
- Transaction value
- $9,581
- Shares
- -9,125
- Change %
- -18%
- Price
- $1.05
- Shares after
- 41,813
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -27,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 81,000
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,000
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
Footnote F2
The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
Footnote F3
On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.